title: Development and initial characterization of a mitomycin C-resistant colon cancer cell line variant.
abstract: Resistance may limit the clinical usefulness of a variety of chemotherapeutic drugs, including mitomycin C (MMC). In order to study resistance to MMC, a variant of the HT-29 human colon cell line was isolated by exposure to repeated doses of MMC. The 95% inhibitory concentration of MMC for this isolate (HT-29R13) was found to be approximately twice that for the parent line. The level of resistance did not increase with additional drug exposure, and resistance was stable for at least 6 months in the absence of drug exposure. HT-29R13 cells exhibit cross-resistance to melphalan and 5-FU but not to doxorubicin, cis-platinum, or etoposide. HT-29R13 cells are characterized by slightly decreased plating efficiency and slightly increased total protein compared with the parent line. This model of stable, low-level MMC resistance with an unusual cross-resistance pattern may prove useful for the study and characterization of MMC resistance mechanisms.
authors.affiliation: Department of Surgery, Eastern Virginia Medical School, Norfolk 23507-1912.
authors.forename: R R
authors.initials: RR
authors.lastname: Perry
authors.forename: B R
authors.initials: BR
authors.lastname: Greaves
authors.forename: Y
authors.initials: Y
authors.lastname: Kang
mesh_terms: D002453:Cell Cycle / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D003110:Colonic Neoplasms / Q000473:pathology*; D004351:Drug Resistance; D006801:Humans; D016685:Mitomycin / Q000494:pharmacology*; D014407:Tumor Cells, Cultured / Q000187:drug effects*
chemical_list: D016685:Mitomycin